|
U.S Government Continues Support for Clinical Development of Adjuvanted Vaccine
ATLANTA, GA - August 16, 2011- GeoVax Labs, Inc. (OTCBB:GOVX), an Atlantabased,
biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus
(HIV) infections, today announced receipt of a $3.6 million annual notice of award for the Integrated
Preclinical/Clinical AIDS Vaccine Development (IPCAVD) Grant supporting GeoVax's HIV/AIDS
vaccine program.
This grant was originally awarded in 2007 to GeoVax by the National Institutes of Health-National
Institute of Allergy & Infectious Disease (NIH-NIAID), an agency of the U.S. Government. Only
meritorious HIV/AIDS prevention vaccine candidates are considered to receive an IPCAVD award. This
most recent annual award represents the fifth year's award, bringing the aggregate award to date to $19.6
million. GeoVax will utilize this funding to further production of its GM-CSF adjuvanted vaccine for
planned human clinical trials.
"This award will allow us to maintain momentum on the successful development of our GM-CSF
adjuvanted vaccine," said Harriet Robinson, Ph.D., Chief Scientific Officer of GeoVax and Program
Director for the Award. "Depending on FDA submission schedules, we anticipate beginning a Phase 1
clinical trial within the next six months. The exciting thing about using the GM-CSF adjuvant is that it
significantly increases prevention of infection. Without the adjuvant, our vaccine has been demonstrated
to successfully control infection, but prevention of infection is the ultimate goal. There is widespread
enthusiasm and desire for a vaccine that provides the promise for prevention of infection."
"We just had our annual External Advisory Board Meeting for our GM-CSF adjuvant project," said
Robert McNally, Ph.D., President & CEO of GeoVax. "It was very productive with the outside experts
being highly enthusiastic about the GM-CSF adjuvanted vaccine and very complimentary of the progress
GeoVax has made."
###
About GeoVax Labs, Inc.
GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human
Immunodeficiency Virus - that leads to AIDS) and other infectious agents. Our goals include developing
HIV/AIDS vaccines for global markets, overseeing the manufacture and testing of these vaccines under
GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness,
and obtaining regulatory approvals to move the product forward. GeoVax's vaccines are unique in
expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope
glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations
and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic
T cell) immune responses, as well as, the vaccines' safety. Successful results from Phase 1
testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January
2009 and will ultimately involve 300 participants at sites in the United States and South America.
Recently GeoVax began enrolling patients in a Phase 1 therapeutic trial for individuals individuals already
infected with HIV. For more information, please visit www.geovax.com.
Forward-Looking Statements
As a cautionary note to investors, certain matters discussed in this press release may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters
involve risks and uncertainties that may cause actual results to differ materially, including the following:
changes in economic conditions; general competitive factors; acceptance of the Company's products in
the market; the Company's success in technology and product development; the Company's ability to
execute its business model and strategic plans; and all the risks and related information described from
time to time in the Company's SEC filings, including the financial statements and related information
contained in the Company's SEC Filing. GeoVax assumes no obligation to update the information in this
release.
Contact
The Investor Relations Group:
Erika Moran, Investor Relations
Janet Vasquez, Public Relations
(212) 825-3210
"Reproduced with permission - GeoVax Labs, Inc."
GeoVax Labs, Inc.
|
